TBPH
Theravance Biopharma Inc

1,031
Mkt Cap
$726.14M
Volume
1.49M
52W High
$21.03
52W Low
$7.90
PE Ratio
7.07
TBPH Fundamentals
Price
$14.33
Prev Close
$14.01
Open
$14.07
50D MA
$17.97
Beta
0.57
Avg. Volume
506,057.61
EPS (Annual)
$2.06
P/B
3.12
Rev/Employee
$1.11M
$680.10
Loading...
Loading...
News
all
press releases
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Zacks Research
Zacks Research upgraded shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Thursday...
MarketBeat·18h ago
News Placeholder
More News
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street Zen
Wall Street Zen lowered shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a research note on Saturday...
MarketBeat·24h ago
News Placeholder
Theravance's Q4 Earnings and Revenues Miss Estimates
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.
Zacks·1d ago
News Placeholder
All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy
Theravance Bio (TBPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks·2d ago
News Placeholder
Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·2d ago
News Placeholder
BTIG Research Reaffirms "Buy" Rating for Theravance Biopharma (NASDAQ:TBPH)
BTIG Research restated a "buy" rating and issued a $21.00 price objective on shares of Theravance Biopharma in a research note on Friday...
MarketBeat·2d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Beats Estimates By $0.71 EPS
Theravance Biopharma (NASDAQ:TBPH - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating...
MarketBeat·2d ago
News Placeholder
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -86.47% and -23.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) SVP Rhonda Farnum Sells 31,067 Shares of Stock
Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the sale, the senior vice...
MarketBeat·3d ago
News Placeholder
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial...
PR Newswire·3d ago
<
1
2
...
>

Latest TBPH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.